Inhaled Sodium Pyruvate ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	2

299. 嚢胞性線維症

---

臨床試験数 : 1,696 /  薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00308243 (ClinicalTrials.gov)	March 2006	27/3/2006	Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.	Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study. Stage 1)	Cystic Fibrosis	Drug: Sodium Pyruvate in 0.9% Sodium Chloride Solution	Emphycorp	Cellular Sciences	Completed	18 Years	N/A	Both	15	Phase 1	United States
2	NCT00332215 (ClinicalTrials.gov)	February 2006	30/5/2006	A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.	Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study.	Cystic Fibrosis	Drug: Inhaled Sodium Pyruvate	University of Minnesota - Clinical and Translational Science Institute	Cellular Sciences	Terminated	18 Years	N/A	Both	70	Phase 1	United States